Clinical Scorecard: Schistosomiasis: The Need for a Tailored-Made Treatment for Preschoolers
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Parasitic disease causing chronic inflammation and organ damage, particularly affecting growth and cognitive development in children, leading to long-term health issues. |
| Target Population | |
| Care Setting |
Key Highlights
- Praziquantel is effective for school-aged children and adults but unsuitable for preschoolers due to large tablet size and bitter taste. The new formulation received WHO prequalification in May 2024 and was added to the WHO Essential Medicine List in September 2025.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor for treatment efficacy and adverse effects in young children, including specific metrics such as growth parameters and cognitive assessments.
Risks
Patient & Prescribing Data
Preschool-aged children (3 months to 6 years) at risk of schistosomiasis.
New formulation developed to improve adherence and safety in young children.
Clinical Best Practices
- Engage in collaborative efforts to develop pediatric-specific medications, including partnerships with academic institutions and NGOs.
- Utilize advanced taste-masking technologies, such as flavoring agents and alternative delivery systems, to improve medication acceptance among young children.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
